• Hui Liu, Xue-Fei Ding, Rui Guo, Meng-Fan Zhao, Di Deng, Yu Hao, and Yi Wang.
• Department of Immunology and Microbiology, School of Life Science, Beijing University of Chinese Medicine.
• Medicine (Baltimore). 2020 Aug 28; 99 (35): e21808.

BackgroundViral pneumonia is a common respiratory disease that leads to high mortality around the world. Tanreqing (TRQ) injection has been widely used to treat viral pneumonia in China. However, the efficiency and safety of TRQ injection for viral pneumonia have not been scientifically and methodically evaluated up to now. Thus, this protocol describes a plan of performing a systematic review and meta-analysis to evaluate the efficacy and safety of TRQ injection on patients with viral pneumonia.MethodsOnly randomized controlled trials will be enrolled in our study, and we will search eligible studies in the following electronic databases: PubMed, Embase, Cochrane Central Register of Controlled Trials, Clinical Trials, China National Knowledge Infrastructure, the Wanfang database, the Chinese Scientific Journal Database, and the Sinomed. The total effective rate of clinical efficacy will be used as primary outcome. Time to relieve symptoms, incidence of adverse reactions, and the laboratory parameters will be used as secondary outcomes. Any side effects and adverse events will be recorded and assessed as safety outcomes. Study inclusion, data extraction, and quality assessment will be performed independently by 2 reviewers, and any disagreement will be resolved by a third reviewer. After that, data synthesis and subgroup analysis will be conducted with the Review Manager V.5.3.3 software.ResultsThis review will provide a high-quality synthesis to assess the effectiveness and safety of TRQ injection for viral pneumonia patients.ConclusionOur study will provide comprehensive evidence to decide whether TRQ injection is effective and safe for viral pneumonia patients.Prospero Registration NumberPROSPERO CRD42020164164.

21 keywords...

hide…